AtriCure, Inc. is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. It has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion. The Company also sells Lumitip dissectors and the Estech line of reusable cardiac surgery (valve) instruments. Its cryoICE cryosurgery product line offers various cryoablation devices. Its AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart's left atrial appendage (LAA).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution - NEC
- Sub-Industry: Health Care Equipment
- Symbol: NASDAQ:ATRC
- CUSIP: 04963C20
- Web: www.atricure.com
Capitalization:- Market Cap: $800.45 million
- Outstanding Shares: 33,946,000
Average Prices:- 50 Day Moving Avg: $23.14
- 200 Day Moving Avg: $19.87
- 52 Week Range: $13.45 - $25.11
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -35.73
- P/E Growth: -1.24
Sales & Book Value:- Annual Revenue: $160.44 million
- Price / Sales: 4.99
- Book Value: $4.74 per share
- Price / Book: 4.97
Profitability:- EBIDTA: ($21,000,000.00)
- Net Margins: -21.07%
- Return on Equity: -19.89%
- Return on Assets: -12.25%
Debt:- Debt-to-Equity Ratio: 0.22%
- Current Ratio: 2.79%
- Quick Ratio: 2.12%
Misc:- Average Volume: 168,695 shs.
- Beta: 0.78
- Short Ratio: 14.02
Frequently Asked Questions for AtriCure (NASDAQ:ATRC)
What is AtriCure's stock symbol?
AtriCure trades on the NASDAQ under the ticker symbol "ATRC."
How were AtriCure's earnings last quarter?
AtriCure, Inc. (NASDAQ:ATRC) released its quarterly earnings data on Thursday, May, 4th. The company reported ($0.32) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.01. The firm had revenue of $41.30 million for the quarter, compared to analyst estimates of $40.25 million. AtriCure had a negative net margin of 21.07% and a negative return on equity of 19.89%. The business's quarterly revenue was up 15.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.31) earnings per share. View AtriCure's Earnings History.
When will AtriCure make its next earnings announcement?
Where is AtriCure's stock going? Where will AtriCure's stock price be in 2017?
8 analysts have issued 1 year price targets for AtriCure's stock. Their forecasts range from $19.00 to $26.00. On average, they expect AtriCure's share price to reach $23.25 in the next year. View Analyst Ratings for AtriCure.
What are analysts saying about AtriCure stock?
Here are some recent quotes from research analysts about AtriCure stock:
- 1. According to Zacks Investment Research, "AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart. " (5/10/2017)
- 2. Needham & Company LLC analysts commented, "ATRC’s 1Q17 revenue, EBITDA, and EPS beat consensus and management maintained its 2017 guidance. Worldwide Open-Heart Ablation growth improved to 10% from 7% in 4Q16 and US Open-Heart Ablation growth increased to 12% from 1% in 4Q16. We think that the improved Open-Heart growth should help to reduce concerns that this business is in a permanent slowdown and we expect the new guidelines for ablation in concomitant open-heart procedures to drive stronger growth over time. ATRC shares remain at a large discount to peers (2017E EV/ sales of 4.0x vs. small/mid-cap growth peers at a median of 5.8x) and we reiterate our Buy rating." (5/5/2017)
Who are some of AtriCure's key competitors?
Some companies that are related to AtriCure include MiMedx Group (MDXG), CONMED Corporation (CNMD), K2M Group Holdings (KTWO), OraSure Technologies (OSUR), Cardiovascular Systems (CSII), Asante Solutions (PUMP), Orthofix International N.V. (OFIX), Intersect ENT (XENT), CryoLife (CRY), Meridian Bioscience (VIVO), Landauer (LDR), Consort Medical plc (CSRT), Antares Pharma (ATRS), Exactech (EXAC), STAAR Surgical Company (STAA), Invacare Corporation (IVC), Syneron Medical (ELOS) and Sientra (SIEN).
Who are AtriCure's key executives?
AtriCure's management team includes the folowing people:
- Richard M. Johnston, Independent Chairman of the Board
- Michael H. Carrel, President, Chief Executive Officer, Director
- M. Andrew Wade CPA, Chief Financial Officer, Senior Vice President
- Douglas J. Seith, Chief Operating Officer
- Justin J. Noznesky, Senior Vice President, Marketing and Business Development
- Andrew L. Lux Ph.D., Senior Vice President -Operations and Quality
- Mark A. Collar, Independent Director
- Scott William Drake, Independent Director
- Regina E. Groves, Independent Director
- Michael D. Hooven, Independent Director
Who owns AtriCure stock?
AtriCure's stock is owned by many different of institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (2.63%), Bollard Group LLC (0.59%), Rockefeller Financial Services Inc. (0.03%), Bank of Montreal Can (0.03%) and US Bancorp DE (0.01%). Company insiders that own AtriCure stock include Andrew L Lux, Douglas J Seith and Elizabeth D Krell. View Institutional Ownership Trends for AtriCure.
Who sold AtriCure stock? Who is selling AtriCure stock?
AtriCure's stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC. Company insiders that have sold AtriCure stock in the last year include Andrew L Lux and Elizabeth D Krell. View Insider Buying and Selling for AtriCure.
Who bought AtriCure stock? Who is buying AtriCure stock?
How do I buy AtriCure stock?
Shares of AtriCure can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AtriCure's stock price today?
One share of AtriCure stock can currently be purchased for approximately $23.58.
MarketBeat Community Rating for AtriCure (NASDAQ ATRC)MarketBeat's community ratings are surveys of what our community members think about AtriCure and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for AtriCure (NASDAQ:ATRC) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 7 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.88) |
| Consensus Price Target: | $23.25 (1.40% downside) |
Analysts' Ratings History for AtriCure (NASDAQ:ATRC)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 6/16/2017 | Leerink Swann | Reiterated Rating | Outperform | $26.00 | Low |  |
| 5/30/2017 | Piper Jaffray Companies | Reiterated Rating | Overweight -> Overweight | $26.00 | Low | |
| 5/5/2017 | Needham & Company LLC | Reiterated Rating | Buy | $23.00 -> $25.00 | High | |
| 4/17/2017 | Canaccord Genuity | Reiterated Rating | Buy | $22.00 | Low | |
| 3/20/2017 | Northland Securities | Reiterated Rating | Buy | $24.00 | Low | |
| 3/6/2017 | BTIG Research | Downgrade | Buy -> Neutral | | N/A | |
| 8/6/2016 | JMP Securities | Set Price Target | Buy | $23.00 | N/A | |
| 8/5/2016 | Stifel Nicolaus | Lower Price Target | Buy | $26.00 -> $21.00 | N/A | |
| 7/28/2015 | Dougherty & Co | Boost Price Target | Buy | $25.00 -> $30.00 | N/A | |
(Data available from 7/24/2015 forward)
Earnings History for AtriCure (NASDAQ:ATRC)Earnings History by Quarter for AtriCure (NASDAQ ATRC)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 7/27/2017 | | ($0.26) | | | | | N/A | |
| 5/4/2017 | Q1 2017 | ($0.33) | ($0.32) | $40.25 million | $41.30 million | View | Listen | |
| 2/28/2017 | Q4 2016 | ($0.32) | ($0.27) | $41.17 million | $41.20 million | View | Listen | |
| 10/27/2016 | Q316 | ($0.28) | ($0.21) | $10.75 million | $38.34 million | View | Listen | |
| 8/4/2016 | Q216 | ($0.30) | ($0.26) | $39.84 million | $39.70 million | View | Listen | |
| 4/28/2016 | Q116 | ($0.32) | ($0.31) | $36.08 million | $35.90 million | View | Listen | |
| 2/23/2016 | Q415 | ($0.36) | ($0.36) | $35.90 million | $35.90 million | View | Listen | |
| 10/27/2015 | Q315 | ($0.22) | ($0.22) | $31.32 million | $31.40 million | View | Listen | |
| 7/28/2015 | Q215 | ($0.21) | ($0.18) | $30.51 million | $32.58 million | View | Listen | |
| 4/29/2015 | Q115 | ($0.21) | ($0.19) | $28.65 million | $29.90 million | View | Listen | |
| 2/23/2015 | Q414 | ($0.20) | ($0.20) | $28.40 million | $29.40 million | View | Listen | |
| 10/30/2014 | Q314 | ($0.17) | ($0.02) | $25.60 million | $26.70 million | View | Listen | |
| 7/24/2014 | Q214 | ($0.19) | ($0.10) | $25.03 million | $26.51 million | View | Listen | |
| 4/24/2014 | Q114 | ($0.22) | ($0.31) | $23.36 million | $24.80 million | View | Listen | |
| 2/27/2014 | Q413 | ($0.14) | ($0.24) | $21.16 million | $21.90 million | View | Listen | |
| 10/29/2013 | Q313 | ($0.15) | ($0.13) | $18.30 million | $20.10 million | View | Listen | |
| 8/1/2013 | Q2 2013 | ($0.10) | ($0.09) | $19.42 million | $20.40 million | View | Listen | |
| 5/2/2013 | Q1 2013 | ($0.09) | ($0.10) | $18.63 million | $19.43 million | View | Listen | |
| 2/28/2013 | Q4 2012 | ($0.09) | ($0.12) | $18.46 million | $18.40 million | View | Listen | |
| 11/1/2012 | Q312 | ($0.11) | ($0.16) | $17.29 million | $16.10 million | View | N/A | |
| 8/2/2012 | | ($0.07) | ($0.08) | | | View | N/A | |
| 5/2/2012 | | ($0.13) | ($0.10) | | | View | N/A | |
| 11/1/2011 | | ($0.07) | ($0.07) | | | View | N/A | |
| 8/2/2011 | | ($0.01) | ($0.06) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for AtriCure (NASDAQ:ATRC)2017 EPS Consensus Estimate: ($1.09)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.37) | ($0.37) | ($0.37) |
| Q2 2017 | 1 | ($0.29) | ($0.29) | ($0.29) |
| Q3 2017 | 1 | ($0.23) | ($0.23) | ($0.23) |
| Q4 2017 | 1 | ($0.20) | ($0.20) | ($0.20) |
(Data provided by Zacks Investment Research)
Dividend History for AtriCure (NASDAQ:ATRC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for AtriCure (NASDAQ:ATRC)Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 86.46%
Insider Trades by Quarter for AtriCure (NASDAQ:ATRC)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/17/2017 | Elizabeth D Krell | Director | Sell | 10,000 | $21.44 | $214,400.00 | |
| 3/17/2017 | Andrew L Lux | SVP | Sell | 20,000 | $18.85 | $377,000.00 | |
| 11/15/2016 | Elizabeth D Krell | Director | Sell | 10,000 | $19.73 | $197,300.00 | |
| 9/13/2016 | Elizabeth D Krell | Director | Sell | 6,000 | $15.93 | $95,580.00 | |
| 8/17/2016 | Elizabeth D Krell | Director | Sell | 5,000 | $15.20 | $76,000.00 | |
| 3/8/2016 | Elizabeth D Krell | Director | Sell | 10,000 | $16.91 | $169,100.00 | |
| 12/3/2015 | Douglas J. Seith | COO | Sell | 5,000 | $21.55 | $107,750.00 | |
| 12/2/2015 | Elizabeth D. Krell | Director | Sell | 10,000 | $21.88 | $218,800.00 | |
| 11/11/2015 | Elizabeth D. Krell | Director | Sell | 10,000 | $20.68 | $206,800.00 | |
| 4/1/2015 | Michael D Hooven | Director | Sell | 142,268 | $20.81 | $2,960,597.08 | |
| 3/31/2015 | Michael D Hooven | Director | Sell | 20,000 | $20.51 | $410,200.00 | |
| 3/30/2015 | Michael D Hooven | Director | Sell | 85,000 | $21.01 | $1,785,850.00 | |
| 3/13/2015 | Karen P Robards | Director | Sell | 3,150 | $19.53 | $61,519.50 | |
| 3/5/2015 | Douglas J Seith | COO | Sell | 36,688 | $17.51 | $642,406.88 | |
| 3/2/2015 | Elizabeth D Krell | Director | Sell | 10,000 | $17.63 | $176,300.00 | |
| 5/6/2014 | Douglas Seith | SVP | Buy | 1,000 | $15.04 | $15,040.00 | |
| 9/13/2013 | Richard Johnston | Insider | Sell | 77,610 | $10.00 | $776,100.00 | |
| 8/12/2013 | Douglas Seith | SVP | Buy | 10,000 | $9.58 | $95,800.00 | |
| 8/5/2013 | Richard Johnston | Insider | Sell | 20,047 | $10.00 | $200,470.00 | |
| 7/11/2013 | Richard M Johnston | Insider | Sell | 2,343 | $10.00 | $23,430.00 | |
| 6/19/2013 | Richard M Johnston | Insider | Sell | 29,348 | $8.96 | $262,958.08 | |
| 6/18/2013 | Richard M Johnston | Insider | Sell | 39,682 | $9.18 | $364,280.76 | |
| 6/14/2013 | Richard M Johnston | Insider | Sell | 95,598 | $8.97 | $857,514.06 | |
| 6/12/2013 | Richard M Johnston | Insider | Sell | 35,372 | $9.01 | $318,701.72 | |
| 3/6/2013 | James L Lucky | VP | Sell | 50,065 | $8.14 | $407,529.10 | |
| 9/14/2012 | Mark R Lanning | Director | Buy | 11,006 | $7.64 | $84,085.84 | |
| 9/13/2012 | Michael D Hooven | Director | Buy | 1,110 | $7.37 | $8,180.70 | |
| 9/12/2012 | Michael D Hooven | Director | Buy | 1,150 | $7.10 | $8,165.00 | |
| 9/11/2012 | Michael D Hooven | Director | Buy | 1,145 | $7.18 | $8,221.10 | |
| 9/10/2012 | Michael D Hooven | Director | Buy | 1,215 | $7.15 | $8,687.25 | |
| 9/7/2012 | Michael D Hooven | Director | Buy | 1,215 | $6.88 | $8,359.20 | |
| 8/23/2012 | Karen P Robards | Director | Buy | 1,000 | $6.70 | $6,700.00 | |
| 8/16/2012 | Karen P Robards | Director | Buy | 1,000 | $6.98 | $6,980.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for AtriCure (NASDAQ:ATRC)
Latest Headlines for AtriCure (NASDAQ:ATRC)
| Source: |
|
| Date | Headline |
|---|
 | Dayton-area health care firm adds to C-suite
www.bizjournals.com - July 20 at 5:40 PM |
 | AtriCure to Present at the Canaccord Genuity 37th Annual Growth Conference
finance.yahoo.com - July 20 at 5:39 PM |
 | AtriCure, Inc. (NASDAQ:ATRC) Set to Announce Earnings on Thursday
www.americanbankingnews.com - July 20 at 7:40 AM |
 | AtriCure (ATRC) to Hire Salvatore Privitera as New CTO
www.streetinsider.com - July 19 at 3:49 AM |
| AtriCure Announces Hiring of Chief Technology Officer
finance.yahoo.com - July 18 at 5:44 PM |
| ETFs with exposure to AtriCure, Inc. : July 13, 2017
finance.yahoo.com - July 13 at 4:59 PM |
| AtriCure to Announce Second Quarter 2017 Financial Results
finance.yahoo.com - July 6 at 5:29 PM |
| Brokerages Anticipate AtriCure, Inc. (ATRC) Will Post Quarterly Sales of $44.23 Million
www.americanbankingnews.com - July 1 at 9:00 AM |
| AtriCure, Inc. (ATRC) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - June 30 at 12:32 PM |
| Zacks: Brokerages Anticipate AtriCure, Inc. (ATRC) to Announce -$0.25 Earnings Per Share
www.americanbankingnews.com - June 29 at 12:48 PM |
| AtriCure, Inc. (ATRC) Receives Outperform Rating from Leerink Swann
www.americanbankingnews.com - June 16 at 12:34 PM |
| AtriCure, Inc. (ATRC) Raised to Hold at ValuEngine
www.americanbankingnews.com - June 12 at 11:36 PM |
| Analysts Anticipate AtriCure Inc. (ATRC) Will Announce Quarterly Sales of $44.23 Million
www.americanbankingnews.com - June 7 at 11:24 AM |
| Reviewing AtriCure (ATRC) and Integra Lifesciences Holdings Corp (IART)
www.americanbankingnews.com - June 5 at 10:14 PM |
| Head to Head Comparison: Invuity (IVTY) and AtriCure (ATRC)
www.americanbankingnews.com - June 5 at 8:46 PM |
| AtriCure Inc. (ATRC) Expected to Post Earnings of -$0.25 Per Share
www.americanbankingnews.com - June 5 at 10:52 AM |
| AtriCure Inc. (ATRC) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 5 at 9:15 AM |
| Piper Jaffray Assumes AtriCure Inc. (ATRC) to Overweight
www.streetinsider.com - May 30 at 12:35 PM |
| Piper Jaffray Companies Initiates Coverage on AtriCure Inc. (ATRC)
www.americanbankingnews.com - May 30 at 10:42 AM |
| AtriCure to Present at the JMP Securities Life Science Conference
finance.yahoo.com - May 18 at 12:03 PM |
| Elizabeth D. Krell Sells 10,000 Shares of AtriCure Inc. (ATRC) Stock
www.americanbankingnews.com - May 17 at 7:47 PM |
| AtriCure Inc. (ATRC) Upgraded by TheStreet to C-
www.americanbankingnews.com - May 17 at 6:32 PM |
| ETFs with exposure to AtriCure, Inc. : May 12, 2017
finance.yahoo.com - May 12 at 4:16 PM |
| AtriCure, Inc. :ATRC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
finance.yahoo.com - May 10 at 8:53 PM |
| AtriCure Inc. (ATRC) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 10 at 7:36 PM |
| AtriCure Inc. (ATRC) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 9 at 10:28 PM |
| Brokerages Anticipate AtriCure Inc. (ATRC) Will Announce Earnings of -$0.24 Per Share
www.americanbankingnews.com - May 9 at 8:28 PM |
| AtriCure Inc. (ATRC) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - May 9 at 9:25 AM |
| Needham & Company LLC Reaffirms "Buy" Rating for AtriCure Inc. (ATRC)
www.americanbankingnews.com - May 6 at 2:04 PM |
| AtriCure Inc. (ATRC) Posts Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - May 5 at 3:58 PM |
| Here's Why ArtiCure, Inc. Is Up Double-Digits Today
finance.yahoo.com - May 5 at 3:44 PM |
| Edited Transcript of ATRC earnings conference call or presentation 4-May-17 8:30pm GMT
finance.yahoo.com - May 5 at 3:44 PM |
| AtriCure Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 4 at 8:48 PM |
| AtriCure reports 1Q loss
finance.yahoo.com - May 4 at 8:48 PM |
| AtriCure (ATRC) Receives Daily News Sentiment Rating of 0.31
www.americanbankingnews.com - May 2 at 12:20 PM |
| AtriCure Inc. (ATRC) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - May 2 at 9:58 AM |
 | Thoughts On Consonance Capital's Positions - Part 2
seekingalpha.com - April 30 at 2:19 AM |
| AtriCure (ATRC) Receives Media Impact Rating of 0.16
www.americanbankingnews.com - April 29 at 9:58 AM |
| AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide
finance.yahoo.com - April 25 at 11:22 AM |
| AtriCure (ATRC) Receiving Somewhat Favorable Press Coverage, Analysis Finds
www.americanbankingnews.com - April 24 at 6:00 PM |
| AtriCure (ATRC) Earns Media Sentiment Rating of 0.06
www.americanbankingnews.com - April 20 at 3:25 PM |
| AtriCure Inc. (ATRC) Expected to Announce Quarterly Sales of $40.34 Million
www.americanbankingnews.com - April 20 at 10:01 AM |
| Brokerages Anticipate AtriCure Inc. (ATRC) Will Post Earnings of -$0.33 Per Share
www.americanbankingnews.com - April 19 at 12:15 AM |
| AtriCure's (ATRC) "Buy" Rating Reaffirmed at Canaccord Genuity
www.americanbankingnews.com - April 17 at 9:10 PM |
| Somewhat Favorable News Coverage Unlikely to Impact AtriCure (ATRC) Stock Price
www.americanbankingnews.com - April 17 at 4:04 PM |
| AtriCure (ATRC) Receiving Positive Press Coverage, Analysis Finds
www.americanbankingnews.com - April 14 at 5:21 PM |
| AtriCure Inc. (ATRC) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 14 at 10:41 AM |
| AtriCure to Announce First Quarter 2017 Financial Results
finance.yahoo.com - April 7 at 8:42 PM |
| ETFs with exposure to AtriCure, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 8:12 AM |
| Canaccord Genuity Reaffirms "Buy" Rating for AtriCure Inc. (ATRC)
www.americanbankingnews.com - April 2 at 11:06 AM |
AtriCure (ATRC) Chart for Monday, July, 24, 2017
